Clinical and Laboratory Factors Associated with Severe Disease Course in Turkish Patients with COVID-19 Infection

被引:1
|
作者
Ak, Cagatay [1 ]
Sayar, Suleyman [1 ]
Polat, Zeynep Pelin [2 ]
Kilic, Ebru Tarikci [3 ]
Ozdil, Kamil [1 ]
机构
[1] Univ Hlth Sci, Umraniye Training & Res Hosp, Dept Gastroenterol, Istanbul, Turkey
[2] Univ Hlth Sci, Umraniye Training & Res Hosp, Dept Internal Med, Istanbul, Turkey
[3] Univ Hlth Sci, Umraniye Training & Res Hosp, Dept Anesthesiol, Istanbul, Turkey
关键词
COVID-19; Risk factors of severe pneumonia; SARS-CoV-2; Severe disease;
D O I
10.32592/ircmj.2021.23.2.283
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Coronavirus disease 2019 (COVID-19) can have a wide clinical spectrum. Objectives: The current study aimed to analyze the clinical and laboratory risk factors of the severe course of disease in patients with COVID-19. Methods: Consecutive patients with a diagnosis of COVID-19 pneumonia were included in the present study. The demographic characteristics, comorbid diseases, symptoms, chest computed tomography (CT) findings, laboratory data, oxygen saturation (SpO(2)), and body temperature of the patients were recorded. The coexistence of pulmonary infiltration in CT and SpO(2) of <= %93 on fingertip pulse oximeter was defined as the severe course of the disease. Results: A total of 475 patients were included in the current study. The mean age of the patients was 52.02 +/- 15.9 years, and 259 (54.5%) participants were male. The disease was mild and severe in 80% (n=380) and 20% (n=95) of the study subjects, respectively. The age of > 50 years, coexistence of hypertension (HT) and diabetes mellitus (DM), neutrophil-to-lymphocyte ratio (NLR) of > 4, lactate dehydrogenase (LDH) of > 240 U/L, C-reactive protein (CRP) of > 8 mg/dL, and D-dimer of >= 1000 ng/mL were determined to be the risk factors for the severe course of the disease. Conclusion: Age, NLR, CRP, LDH, D-dimer, comorbidity, and coexistence of DM and HT were the independent risk factors for the severe course of the disease. The aforementioned factors should be taken into account during risk stratification and management of patients with COVID-19.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] INVESTIGATION OF THE CLINICAL COURSE AND SEVERITY OF COVID-19 INFECTION IN IMMUNOCOMPROMISED PATIENTS
    Ozturk, Sinan
    Kant, Aydin
    Comoglu, Senol
    Ertunc, Baris
    Yilmaz, Gurdal
    ACTA MEDICA MEDITERRANEA, 2021, 37 (05): : 2593 - 2597
  • [22] Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19
    Dixit, Deepali
    Jen, Polly
    Maxwell, Tyler D.
    Smoke, Steven
    McCracken, James Andrew
    Cardinale-King, Maria
    Haribhakti, Aditi
    Patel, Purvi
    Cani, Eris
    Choi, Seohyun
    Jagpal, Sugeet
    Varughese, Tilly
    Tatem, Luis L.
    Bhowmick, Tanaya
    CRITICAL CARE EXPLORATIONS, 2022, 4 (09) : E0762
  • [23] Risk and protective factors for severe COVID-19 infection in a cohort of patients with sickle cell disease
    Cai, Jessi
    Chen-Goodspeed, Amber
    Idowu, Modupe
    JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (05) : 1243 - 1246
  • [24] Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population
    Mostaza, Jose M.
    Garcia-Iglesias, Francisca
    Gonzalez-Alegre, Teresa
    Blanco, Francisco
    Varas, Marta
    Hernandez-Blanco, Clara
    Hontanon, Victor
    Jaras-Hernandez, Maria J.
    Martinez-Prieto, Monica
    Menendez-Saldana, Araceli
    Cachan, Maria L.
    Estirado, Eva
    Lahoz, Carlos
    de Miguel, Rosa
    Romero, Miriam
    Lago, Mar
    Garcia-Quero, Cristina
    Plaza, Cristina
    Sainz-Costa, Talia
    Rivas-Vila, Susana
    Sanchez, Blanca
    Torres, Celia Garcia
    Martinez-Tobar, Lucia
    Hernandez-Perez, Maria
    Racionero, Pablo
    Mir-Ihara, Patricia
    Pena-Lopez, Jesus
    Bautista-Barea, Marta
    Benitez, Alexa P.
    Rodriguez-Merlos, Pablo
    Barcenilla, Maria
    San Basilio, Maria
    Valencia, Maria
    Romero-Martin, Ricardo
    de los Bueis, Ana Boto
    de la Hoz-Polo, Adriana
    del Pino-Cidad, Maria
    Coca-Robinot, Javier
    Gonzalez-Ferrer, Barbara
    Fernandez-Perez, Pedro
    Mogollon, Isabel
    Montoro-Romero, Maria S.
    Villalain, Isabel
    del Hierro-Zarzuelo, Almudena
    Hernandez-Martin, Irene
    Dominguez, Javier
    Luna, Alberto
    Montoro, Soledad
    Sanchez-Orgaz, Margarita
    Amorena, Gloria
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2020, 91
  • [25] COVID-19 in multiple sclerosis patients and risk factors for severe infection
    Chaudhry, Farhan
    Bulka, Helena
    Rathnam, Anirudha S.
    Said, Omar M.
    Lin, Jia
    Lorigan, Holly
    Bernitsas, Eva
    Rube, Jacob
    Korzeniewski, Steven J.
    Memon, Anza B.
    Levy, Phillip D.
    Schultz, Lonni
    Javed, Adil
    Lisak, Robert
    Cerghet, Mirela
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 418
  • [26] Clinical and Laboratory Factors Associated with Symptom Development in Asymptomatic COVID-19 Patients at the Time of Diagnosis
    Oh, Hong Sang
    Kim, Joon Ho
    Woo, Myoung Lyeol
    Kim, Ji-Yeon
    Park, Chul Hee
    Won, Hyejin
    Lim, Seungkwan
    Jeong, Hyeonju
    Ham, Sin Young
    Kim, Eun Jin
    Sheen, Seungsoo
    Kang, Yu Min
    Yoon, Doran
    Lee, Seung Youp
    Song, Kyoung-Ho
    INFECTION AND CHEMOTHERAPY, 2021, 53 (04) : 786 - 791
  • [27] COVID-19 among patients with epilepsy: Risk factors and course of the disease
    Bosak, Magdalena
    Mazurkiewicz, Iwona
    Wezyk, Kamil
    Slowik, Agnieszka
    Turaj, Wojciech
    EPILEPSY & BEHAVIOR, 2021, 120
  • [28] COVID-19 disease induced alteration of oxidative stress and clinical laboratory parameters in moderate and severe patients
    Zendelovska, D.
    Petrushevska, M.
    Atanasovska, E.
    Spasovska, K.
    Gjorgjievska, K.
    Pavlovska, K.
    Grozdanovski, K.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (15) : 5611 - 5617
  • [29] Factors Associated with Severe COVID-19 Infections in Lung Cancer Patients
    Ganti, A. K.
    Fillmore, N.
    La, J.
    Bihn, J.
    Kelley, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S921 - S922
  • [30] Effect of tofacitinib on clinical and laboratory findings in severe and resistant patients with COVID-19
    Almasi, Simin
    Rashidi, Azadeh
    Kachuee, Manizhe Ataee
    Shirazi, Bentolhoda Mohammad
    Izadi, Shirin
    Ghaffarpour, Sara
    Azimi, Mehdi
    Naghizadeh, Mohammad Mehdi
    Makiani, Mahin Jamshidi
    Ranjbar, Mitra
    Goudarzi, Manizheh
    Rahimian, Neda
    Ghazanfari, Tooba
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122